Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.27 USD
Change Today +0.004 / 1.51%
Volume 644.5K
ONCS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

9810 Summers Ridge Road

Suite 110

San Diego, CA 92121

United States

Phone: 855-662-6732

Fax: 858-430-3832

OncoSec Medical Incorporated operates as a hybrid device and gene therapy biotechnology company. The company focuses on designing, developing, and commercializing innovative and proprietary medical approaches for the treatment of cancer. The company’s portfolio includes biologic immunotherapy product candidates intended to treat a range of tumor types. Its technology includes intellectual property relating to certain delivery technologies, which it refers to as ImmunoPulse, a therapeutic approach that is based on the use of an electroporation delivery device in combination with DNA-encoded immune targets to treat cancer. The company’s electroporation devices consist of an electrical pulse generator and disposable applicators, which could be adapted to treat tumors differing in histologic type, size, and location. Using ImmunoPulse, the company’s DNA-based immunotherapy is to treat cancer. Immunotherapy, a process, which uses the patient’s own immune system to treat cancer, might have advantages over surgery, radiation, and chemotherapy. The company’s primary product candidate, an immunotherapy for metastatic melanoma, is being studied in a Phase 2 open label clinical trial. Based on the safety and efficacy of intratumoral electroporation of DNA plasmid IL-12 (pIL-12) in the Phase 1 and ongoing Phase 2 studies, the company intends to pursue a Phase 2b study to evaluate the safety and efficacy of intratumoral electroporation of pIL-12 in combination with an anti-PD-1/PDL-1 therapeutic. In addition, the company’s portfolio includes an asset that utilizes electroporation delivery with a small molecule drug, which it refers to as NeoPulse. Its NeoPulse approach utilizes its electroporation technologies for the local delivery of a small molecule drug (bleomycin) to treat tumors. University of South Florida License In 2012, the company secured a license for specific patented technology from the University of South Florida Research Foundation relating to the delivery of gene-based therapeutics through intratumoral and intramuscular electroporation. This patent directly supports its clinical development focus in solid tumor applications and specifically metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma using its ImmunoPulse therapy, and extends patent protection for the ImmunoPulse technology to the year 2024. Electroporation Delivery The electroporation delivery consists of an electrical pulse generator and various disposable applicators specific to the individual tumor size, type, and location. A Phase I clinical trial in metastatic melanoma has been completed using electroporation to deliver plasmid-DNA encoding for the IL-12 cytokine. A Phase II clinical trial in metastatic melanoma has also been completed. The company intends to expand its ImmunoPulse pipeline beyond the delivery of plasmid-DNA encoding for cytokines with a focus on targeting key pathways of tumor immune subversion. Clinical Program The company initiated three Phase 2 clinical trials to assess the safety and efficacy of its ImmunoPulse technology with DNA-encoded IL-12 in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma during 2012. Its major ImmunoPulse candidate for these trials is a DNA plasmid coding for IL-12 that is delivered using the company’s electroporation device. Strategy The company’s clinical development strategy includes completing the necessary additional clinical trials in accordance with the United States Food and Drug Administration (the ‘FDA’) guidelines for cancers, including select, rare cancers (orphan indications) that have limited therapeutic options. Its strategy also includes expanding the applications of its technologies through strategic collaborations or evaluation of other opportunities, such as in-licensing and strategic acquisitions. Intellectual Property The company owns and has been issued 27 U.S. patents and has 2 U.S. patent applications pending. It expects to file additional patent applications. The company has a total of 18 issued patents and patent applications in other jurisdictions. The bulk of its patents, including fundament

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.27 USD +0.004

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit www.oncosec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.